Diagnostic significance of the combination of serum CCL20 and Oncostatin M for early-stage endometrial cancer

Our study aimed to preliminarily investigate the role of combined detection of serum CCL20 and Oncostatin M in the diagnosis of early-stage endometrial cancer (EC). A retrospective study was conducted on 109 patients with early-stage EC. Serum CCL20 and Oncostatin M levels were determined, and their correlations with sex hormone indicators (TTE and DHEAS) in EC patients were analyzed. Influencing factors for EC and the early diagnostic value of each indicator were analyzed. Serum CCL20 and Oncostatin M were high in EC patients and positively correlated with TTE and DHEAS. Elevated CCL20 and Oncostatin M were independent risk factors for EC. The diagnostic efficacy of serum CCL20 + Oncostatin M in combination was better than that of serum CCL20, Oncostatin M, CA125, and HE4 alone. The diagnostic test combining serum CCL20 and Oncostatin M in endometrioid carcinoma demonstrated an AUC of 0.855, with a sensitivity of 68.00% and a specificity of 92.86%, comparable to that in the whole early-stage endometrial carcinoma group (AUC = 0.867). Combined detection of serum CCL20 and Oncostatin M may offer a promising adjunctive approach for the diagnosis of early-stage EC, with their levels correlated to sex hormone and clinicopathological characteristics.